X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25658) 25658
Newsletter (87) 87
Book Chapter (20) 20
Dissertation (15) 15
Magazine Article (13) 13
Newspaper Article (4) 4
Book / eBook (3) 3
Publication (3) 3
Book Review (1) 1
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21425) 21425
female (15692) 15692
male (13821) 13821
middle aged (13616) 13616
oncology (13491) 13491
cisplatin (13104) 13104
aged (11886) 11886
adult (11184) 11184
chemotherapy (10880) 10880
cisplatin - administration & dosage (9891) 9891
antineoplastic combined chemotherapy protocols - therapeutic use (9736) 9736
cisplatin - adverse effects (8540) 8540
antineoplastic combined chemotherapy protocols - adverse effects (8023) 8023
cancer (7833) 7833
treatment outcome (5468) 5468
antineoplastic agents - adverse effects (4036) 4036
lung neoplasms - drug therapy (3606) 3606
neoplasm staging (3517) 3517
animals (3039) 3039
combined modality therapy (3035) 3035
drug administration schedule (3011) 3011
care and treatment (2952) 2952
cisplatin - therapeutic use (2952) 2952
radiotherapy (2857) 2857
aged, 80 and over (2840) 2840
carcinoma (2797) 2797
survival rate (2681) 2681
disease-free survival (2601) 2601
pharmacology & pharmacy (2577) 2577
fluorouracil - administration & dosage (2509) 2509
therapy (2494) 2494
trial (2441) 2441
carcinoma, non-small-cell lung - drug therapy (2374) 2374
antineoplastic agents - therapeutic use (2371) 2371
retrospective studies (2371) 2371
carboplatin (2353) 2353
survival (2300) 2300
antineoplastic combined chemotherapy protocols - administration & dosage (2281) 2281
paclitaxel (2280) 2280
survival analysis (2265) 2265
research (2163) 2163
toxicity (2151) 2151
prognosis (2091) 2091
medicine & public health (2074) 2074
antineoplastic agents - administration & dosage (1958) 1958
surgery (1928) 1928
deoxycytidine - analogs & derivatives (1881) 1881
carcinoma, squamous cell - drug therapy (1861) 1861
follow-up studies (1839) 1839
ovarian neoplasms - drug therapy (1800) 1800
adolescent (1796) 1796
carboplatin - administration & dosage (1769) 1769
gemcitabine (1749) 1749
dose-response relationship, drug (1706) 1706
paclitaxel - administration & dosage (1688) 1688
lung neoplasms - pathology (1687) 1687
analysis (1668) 1668
etoposide - administration & dosage (1667) 1667
antineoplastic agents (1661) 1661
tumors (1648) 1648
combination (1644) 1644
hematology, oncology and palliative medicine (1580) 1580
deoxycytidine - administration & dosage (1564) 1564
neoplasms - drug therapy (1548) 1548
prospective studies (1547) 1547
docetaxel (1527) 1527
antimitotic agents (1471) 1471
5-fluorouracil (1458) 1458
doxorubicin - administration & dosage (1458) 1458
metastasis (1441) 1441
fluorouracil (1428) 1428
vomiting - chemically induced (1425) 1425
cancer therapies (1423) 1423
health aspects (1384) 1384
clinical trials (1375) 1375
apoptosis (1366) 1366
time factors (1365) 1365
adenocarcinoma - drug therapy (1354) 1354
patients (1330) 1330
phase-ii (1317) 1317
doxorubicin (1310) 1310
lung cancer (1301) 1301
chemotherapy, adjuvant (1293) 1293
stomach neoplasms - drug therapy (1293) 1293
drug therapy (1277) 1277
radiation-therapy (1228) 1228
carboplatin - adverse effects (1227) 1227
carcinoma, non-small-cell lung - pathology (1221) 1221
mice (1215) 1215
squamous-cell carcinoma (1209) 1209
risk factors (1206) 1206
nausea - chemically induced (1204) 1204
fluorouracil - adverse effects (1200) 1200
infusions, intravenous (1199) 1199
etoposide (1170) 1170
drug therapy, combination (1162) 1162
lung neoplasms - mortality (1152) 1152
chemoradiotherapy (1151) 1151
obstetrics & gynecology (1127) 1127
rats (1066) 1066
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24364) 24364
Japanese (935) 935
French (270) 270
Chinese (251) 251
German (210) 210
Spanish (83) 83
Russian (71) 71
Italian (51) 51
Polish (29) 29
Hungarian (25) 25
Portuguese (17) 17
Korean (11) 11
Dutch (10) 10
Czech (9) 9
Bulgarian (7) 7
Danish (4) 4
Ukrainian (4) 4
Hebrew (3) 3
Norwegian (3) 3
Serbian (3) 3
Swedish (3) 3
Turkish (3) 3
Romanian (2) 2
Slovak (2) 2
Bosnian (1) 1
Croatian (1) 1
Finnish (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


04/2000, Volume 22, Issue 4, 40
Cytostatic antibiotics of the anthracycline class are the best known of the chemotherapeutic agents that cause cardiotoxicity. Alkylating agents such as... 
Mitomycin, adverse reactions | Tretinoin, adverse reactions | Etoposide, adverse reactions | Cladribine, adverse reactions | Heart disorders, drug-induced | Pentostatin, adverse reactions | Vinca alkaloids, adverse reactions | Cytostatic antibiotics, adverse reactions | Fluorouracil, adverse reactions | Asparaginase, adverse reactions | Cisplatin, adverse reactions | Carmustine, adverse reactions | Amsacrine, adverse reactions | Ifosfamide, adverse reactions | Mitoxantrone, adverse reactions | Cyclophosphamide, adverse reactions | Cytarabine, adverse reactions | Paclitaxel, adverse reactions | Teniposide, adverse reactions | Antineoplastics, adverse reactions | Busulfan, adverse reactions | Chlormethine, adverse reactions | HEMOLYTIC-UREMIC SYNDROME | SOFT-TISSUE SARCOMAS | HAIRY-CELL LEUKEMIA | PHASE-II TRIAL | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | BONE-MARROW TRANSPLANTATION | HIGH-DOSE CYCLOPHOSPHAMIDE | SOUTHWEST-ONCOLOGY-GROUP | ACUTE LYMPHOBLASTIC-LEUKEMIA | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CONGESTIVE-HEART-FAILURE | Antineoplastic Agents - adverse effects | Humans | Risk Factors | Antimetabolites, Antineoplastic - adverse effects | Antibiotics, Antineoplastic - adverse effects | Heart Diseases - prevention & control | Antineoplastic Agents, Alkylating - adverse effects | Heart Diseases - chemically induced | Angiogenesis Inhibitors - adverse effects
Book Review
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 32, pp. 3651 - 3658
Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in... 
TRIAL | MORTALITY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | INVOLVED-FIELD RADIATION | PEDIATRIC-PATIENTS | DISEASE | FOLLOW-UP | CHILDHOOD-CANCER SURVIVOR | NO RADIOTHERAPY | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Blood, ISSN 1528-0020, 2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, pp. CD011746 - CD011746
Background Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocarcinomas,... 
Medical interventions | MALIGNANT CHOLANGIOCARCINOMA INCLUDING PERIAMPULLAR CANCER (C24.1) (M8160/3) | Capecitabine | Organoplatinum Compounds | Tegafur | Gemcitabine‐based therapy | Biliary Tract Neoplasms | Gallbladder & bile duct disease | Quinazolines | Ampulla of Vater | MALIGNANT COMBINED HEPATO‐CELLULAR CHOLANGIOCARCINOMA (C22.0) (M8180/3) | Oxaliplatin | Oxonic Acid | Piperidines | Cholangiocarcinoma | Medical intervention | Chemotherapeutic agents | Mitomycin | Gastroenterology & hepatology | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Gallbladder cancer | Randomized Controlled Trials as Topic | Treatment | Deoxycytidine | Gallbladder Neoplasms | Antimetabolites, Antineoplastic | Other types of cancer | Medicine General & Introductory Medical Sciences | Drug Combinations | Cancer | MEDICINE, GENERAL & INTERNAL | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | RANDOMIZED PHASE-II | DESIGN CHARACTERISTICS | FINDINGS TABLES | EMPIRICAL-EVIDENCE | GALLBLADDER CANCER | POOLED ANALYSIS | SINGLE-AGENT GEMCITABINE | TRIAL SEQUENTIAL-ANALYSIS | Capecitabine - administration & dosage | Gallbladder Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biliary Tract Neoplasms - mortality | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Mitomycin - adverse effects | Piperidines - administration & dosage | Tegafur - adverse effects | Cholangiocarcinoma - mortality | Oxonic Acid - administration & dosage | Oxonic Acid - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Capecitabine - adverse effects | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Gallbladder Neoplasms - pathology | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10103, pp. 1654 - 1663
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 1, pp. 13 - 21
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2006, Volume 24, Issue 3, pp. 467 - 475
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2016, Volume 34, Issue 25, pp. 2969 - 2979
Journal Article
Journal of cellular physiology, ISSN 0021-9541, 2019, Volume 234, Issue 5, pp. 5728 - 5740
.... Experimental studies have shown that inflammation plays a central role in tumor resistance and the incidence of several side effects following both chemotherapy and radiotherapy... 
radiotherapy | cancer | inflammation | chemotherapy | curcumin | PHYSIOLOGY | CISPLATIN-INDUCED NEPHROTOXICITY | SYSTEMIC OXIDATIVE STRESS | CANCER STEM-CELLS | HUMAN COLORECTAL-CANCER | CELL BIOLOGY | BONE-MARROW SUPPRESSION | INDUCED ORAL MUCOSITIS | CHRONIC PULMONARY COMPLICATIONS | NF-KAPPA-B | RADIATION-INDUCED ACUTE | NORMAL TISSUE-INJURY | Neoplasms - metabolism | Drug-Related Side Effects and Adverse Reactions - prevention & control | Curcumin - therapeutic use | Signal Transduction | Humans | Risk Factors | Drug-Related Side Effects and Adverse Reactions - etiology | Drug-Related Side Effects and Adverse Reactions - metabolism | Radiotherapy - adverse effects | Curcumin - adverse effects | Radiation Injuries - etiology | Neoplasms - therapy | Animals | Anti-Inflammatory Agents - adverse effects | Radiation Injuries - prevention & control | Inflammation Mediators - metabolism | Anti-Inflammatory Agents - therapeutic use | Radiation-Protective Agents - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Radiation Injuries - metabolism | Radiation-Protective Agents - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Toxicity | Clinical trials | Tissues | Dermatitis | Cancer therapies | Metastases | Prostaglandin endoperoxide synthase | Angiogenesis | Bone marrow | Curcumin | Medical research | Mucositis | Free radicals | Cytokines | Tumor cells | Inflammation | Radiation therapy | Nitric-oxide synthase | Side effects | Chemotherapy | Pneumonitis | Nitric oxide | Fibrosis | Nuclear reactions | Cancer | Tumors | Index Medicus
Journal Article